Overview

Combination Treatment for Augmenting Language in Children With ASD

Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The study will consist of two main elements: the enrollment of 72 children aged 6-11 years with ASD and low language competency to receive a thrice-weekly one hour language intervention for 12 weeks; and, beginning at the same time, subjects will be equally randomized to receive either aripiprazole (Abilify) (flexibly dosed from 2-10 mg per day) or placebo for 12 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, Los Angeles
Treatments:
Aripiprazole